Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 2/20 | 0.49 |
| ▸ | NOS2 | P35228 | 4/20 | 0.47 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | BMP1 | P13497 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3558567 | 0.86 | SMN1; SMN2 (0.44) | NOS2NOS1ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL3565071 | 0.84 | MMP9 (0.44) | NOS2NOS1ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL3559611 | 0.83 | SMN1; SMN2 (0.48) | NOS2NOS1HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL3567756 | 0.83 | MEN1 (0.56) | HPGDALDH1A1SMN1; SMN2GAAKDM4E | |
| SCHEMBL3610811 | 0.83 | TDP1 (0.48) | NOS2NOS1HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL3563466 | 0.83 | ALDH1A1 (0.46) | HPGDALDH1A1SMN1; SMN2GAANPSR1 | |
| SCHEMBL3562561 | 0.83 | ALDH1A1 (0.46) | NOS2NOS1HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL3567257 | 0.82 | ALDH1A1 (0.48) | HPGDALDH1A1SMN1; SMN2GAANPSR1 | |
| SCHEMBL3566727 | 0.81 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2GAANPSR1CYP3A4 | |
| SCHEMBL3558583 | 0.81 | NOS2 (0.50) | NOS2NOS1ALDH1A1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825256-B2 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100094021-A1 | NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5YL)-DIALKYL-AMINES | KALYPSYS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20070123572-A1 | NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5YL)-DIALKYL-AMINES | KALYPSYS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094021-A1 | NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5YL)-DIALKYL-AMINES | DCLK2, TH, DCLK3 | HTR5A 89/4885NOS2 983/4885NOS1 777/4885 |
| US-20070123572-A1 | NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5YL)-DIALKYL-AMINES | DCLK2, TH, DCLK3 | HTR5A 89/4885NOS2 983/4885NOS1 777/4885 |
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | NOS3, NOS2, NOS1 | HTR5A 1454/4885NOS2 2/4885NOS1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.